Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data TuHURA Biosciences, Inc./NV files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2024
FY2024
FY2025
Revenue
0
0
0
Research and development
-7.13
3.66
3.63
11.8
15.2
9.31
9.4
2.66
13.3
20.5
General and administrative
-4.04
4.74
4.51
9.76
7.51
5.49
4.14
5.79
3.87
7.58
Operating expenses
-11.2
8.4
-9.2
38.2
22.7
14.8
29.8
8.45
17.6
31.8
Interest expense
0.03
0.02
4.14
0.63
Interest income
0.09
0.36
0.14
Other non-operating income
-0.04
0.35
0.07
-0.13
0.02
0.15
0.45
0.13
-4.03
1.74
Pre-tax income
29.3
-21.7
-30.1
Income tax
0
0
0
Net income
11.1
-8.05
-9.13
-38.3
-22.7
-14.6
-29.3
-8.32
-21.7
-30.1
EPS, basic
268.92
156.79
-43.17
-79.38
-25.80
-9.27
-2.47
-0.32
-1.21
-0.63
EPS, diluted
268.92
156.79
-43.17
-79.38
-25.80
-9.27
-2.47
-0.32
-1.21
-0.63
Shares, basic (weighted)
0.04
0.05
0.21
0.52
0.97
1.62
11.9
26.4
18.7
47.9
Shares, diluted (weighted)
0.04
0.05
0.21
0.52
0.97
1.62
11.9
26.4
18.7
47.9
Balance sheet
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2024
FY2024
FY2025
Cash and equivalents
5.97
3.72
2.39
10.5
11.8
1.54
3.67
4.91
12.7
3.62
Other current assets
1.03
0.28
0.37
0.76
1.48
0.66
0.49
0.41
0.96
0.5
Total current assets
7.05
4.03
2.85
11.8
13.3
3.27
4.16
5.53
19.6
4.62
Property, plant and equipment
0
0.15
0.09
0.71
0.18
0.67
0.12
0.3
Lease right-of-use assets
0.02
0.2
0.38
Goodwill
10.7
Intangible assets
0.03
0.01
0
Other non-current assets
0.03
0.03
Total assets
7.07
4.04
2.94
13.5
15.9
3.98
4.36
6.2
20
27.4
Accounts payable
1.48
1.74
2.01
2.22
3.27
2.78
1.87
1.46
3.15
3.77
Accrued liabilities
1.42
0.74
1.16
1.53
Total current liabilities
1.64
2.07
2.68
2.78
3.99
3.08
3.6
2.26
5.33
5.92
Lease liabilities
0.04
0.3
Total liabilities
1.64
2.07
2.68
2.96
4.15
3.25
5.92
2.45
5.37
6.42
Total debt
0
Paid-in capital
43.2
51
65.1
107
136
141
86.9
153
125
162
Retained earnings
-52.4
-60.6
-69.7
-111
-136
-151
-88.5
-160
-111
-141
Other comprehensive income
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
Shareholders' equity
5.44
1.97
0.26
10.6
11.8
0.73
-1.56
-6.96
14.6
20.9
Total equity
5.44
1.97
0.26
10.6
11.8
0.73
-1.56
-6.96
14.6
20.9
Total liabilities and equity
7.07
4.04
2.94
13.5
15.9
3.98
4.36
6.2
20
27.4
Shares outstanding
0
0
12.2
12.2
59.3
Cash flow statement
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2024
FY2024
FY2025
Net income
-11.1
-8.05
-9.13
-38.3
-22.7
-14.6
-29.3
-8.32
-21.7
-30.1
Depreciation and amortization
0.03
0.06
0.06
0.18
0.06
0.12
0.07
Stock-based compensation
0.5
0.43
0.5
5.28
2.25
1.49
0.48
0.61
1.96
6.42
Deferred income tax
0
0
0
Change in payables
0.3
0.2
0.21
-0.07
1.01
-0.44
0.34
-0.58
3.64
-3.76
Cash from operations
-9.85
-6.33
-7.93
-18.9
-20.4
-11.9
-12
-7.18
-14.7
-27.6
Capital expenditures
-0.08
-0.06
-0.08
Acquisitions
-0.3
-0.3
Cash from investing
-0.01
0.96
-0.23
-1.3
-0.02
-6.05
-1.34
Debt repaid
-0.5
Stock issued
0.08
5
18.3
Share buybacks
-0.02
Cash from financing
9.25
4.07
6.6
26
21.6
1.85
2.66
10.6
29.8
19.9
Net change in cash
-0.61
-2.25
-1.33
8.15
1.24
-10.2
-10.6
3.37
8.99
-9.04
Free cash flow
-12
-14.8
-27.7
Interest paid
0.03
0.06
Income taxes paid
0
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $2.10 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
-165.5%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-96.5%
Net income / average total assets.
Growth
Metric
Value
How it is calculated
Book value growth, 1y
43.4%
Book value vs the same period a year earlier. Only from a positive base.
Total assets growth, 1y
37.0%
Total assets vs the same period a year earlier. Only from a positive base.
Share count change, 1y
156.8%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
0.18x
Current assets / current liabilities.
Quick ratio
0.11x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.11x
(Cash + short-term investments) / current liabilities.
Debt / equity
0.19x
Total debt / shareholders' equity. Not shown when equity is negative.
Debt / assets
11.3%
Total debt / total assets.
Liabilities / assets
41.7%
Total liabilities / total assets.
Net debt
$2.6M
Total debt - cash - short-term investments. Negative means more cash than debt.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
FCF per share
-$0.47
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$0.46
Cash from operations / diluted weighted shares.
Book value per share
$0.29
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/B
7.23x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
17.2x
Market cap / tangible book value, when positive.
FCF yield
-22.3%
Free cash flow / market cap.
Earnings yield
-22.9%
Net income / market cap (the inverse of P/E).
What was TuHURA Biosciences, Inc./NV's revenue in fiscal 2025?
TuHURA Biosciences, Inc./NV reported revenue of $0.0 for fiscal 2025.
Was TuHURA Biosciences, Inc./NV profitable in fiscal 2025?
No. It reported a net loss of $30.1M.
How much free cash flow did TuHURA Biosciences, Inc./NV generate in fiscal 2025?
Cash from operations of $27.6M minus capital expenditures of $76.1K left free cash flow of -$27.7M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.